Resverlogix (RVX) Competitors

C$0.10 -0.01 (-5.00%)

As of 05/25/2026 01:32 PM Eastern

RVX vs. SCYB, COM, NVH, IGX, and PDP

Should you buy Resverlogix stock or one of its competitors? MarketBeat compares Resverlogix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Resverlogix include Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), and Pediapharm (PDP). These companies are all part of the "biotechnology" industry.

How does Resverlogix compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scythian Biosciences	N/A	N/A	N/A	N/A	N/A
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A

Resverlogix's return on equity of 6.67% beat Scythian Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scythian Biosciences	N/A	N/A	N/A
Resverlogix	N/A	6.67%	-34.90%

In the previous week, Resverlogix had 2 more articles in the media than Scythian Biosciences. MarketBeat recorded 2 mentions for Resverlogix and 0 mentions for Scythian Biosciences. Scythian Biosciences' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company	Overall Sentiment
Scythian Biosciences	Neutral
Resverlogix	Neutral

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Resverlogix beats Scythian Biosciences on 4 of the 5 factors compared between the two stocks.

How does Resverlogix compare to 138267 (COM.TO)?

138267 (COM.TO) (TSE:COM) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Resverlogix had 2 more articles in the media than 138267 (COM.TO). MarketBeat recorded 2 mentions for Resverlogix and 0 mentions for 138267 (COM.TO). 138267 (COM.TO)'s average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company	Overall Sentiment
138267 (COM.TO)	Neutral
Resverlogix	Neutral

Resverlogix's return on equity of 6.67% beat 138267 (COM.TO)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
138267 (COM.TO)	N/A	N/A	N/A
Resverlogix	N/A	6.67%	-34.90%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A

Summary

Resverlogix beats 138267 (COM.TO) on 4 of the 5 factors compared between the two stocks.

How does Resverlogix compare to Novoheart?

Resverlogix (TSE:RVX) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Resverlogix's return on equity of 6.67% beat Novoheart's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Resverlogix	N/A	6.67%	-34.90%
Novoheart	N/A	N/A	N/A

In the previous week, Resverlogix had 2 more articles in the media than Novoheart. MarketBeat recorded 2 mentions for Resverlogix and 0 mentions for Novoheart. Resverlogix's average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company	Overall Sentiment
Resverlogix	Neutral
Novoheart	Neutral

Resverlogix has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A
Novoheart	C$423.50K	236.08	-C$7.17M	-C$0.04	N/A

Summary

Resverlogix beats Novoheart on 7 of the 9 factors compared between the two stocks.

How does Resverlogix compare to IntelGenx Technologies?

IntelGenx Technologies (CVE:IGX) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Resverlogix's return on equity of 6.67% beat IntelGenx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IntelGenx Technologies	N/A	N/A	N/A
Resverlogix	N/A	6.67%	-34.90%

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Resverlogix has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IntelGenx Technologies	C$1.75M	49.95	-C$11.74M	-C$0.08	N/A
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A

In the previous week, Resverlogix had 2 more articles in the media than IntelGenx Technologies. MarketBeat recorded 2 mentions for Resverlogix and 0 mentions for IntelGenx Technologies. IntelGenx Technologies' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company	Overall Sentiment
IntelGenx Technologies	Neutral
Resverlogix	Neutral

Summary

Resverlogix beats IntelGenx Technologies on 7 of the 9 factors compared between the two stocks.

How does Resverlogix compare to Pediapharm?

Pediapharm (CVE:PDP) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Resverlogix's return on equity of 6.67% beat Pediapharm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pediapharm	N/A	N/A	N/A
Resverlogix	N/A	6.67%	-34.90%

Resverlogix has lower revenue, but higher earnings than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pediapharm	C$11.16M	5.95	-C$16.15M	-C$0.07	N/A
Resverlogix	N/A	N/A	-C$2.81M	-C$0.03	N/A

In the previous week, Resverlogix had 2 more articles in the media than Pediapharm. MarketBeat recorded 2 mentions for Resverlogix and 0 mentions for Pediapharm. Pediapharm's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company	Overall Sentiment
Pediapharm	Neutral
Resverlogix	Neutral

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Resverlogix beats Pediapharm on 7 of the 9 factors compared between the two stocks.

Get Resverlogix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVX vs. The Competition

Export

Metric	Resverlogix	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$30.11M	C$470.59M	C$6.46B	C$12.16B
Dividend Yield	7.02%	3.87%	2.76%	6.20%
P/E Ratio	-3.17	3.86	21.21	37.64
Price / Sales	N/A	7,288.62	554.38	11.68
Price / Cash	132.50	13.13	43.49	82.29
Price / Book	-0.32	84.78	10.37	4.50
Net Income	-C$2.81M	-C$96.07M	C$3.57B	C$299.09M
7 Day Performance	N/A	0.04%	6.40%	2.48%
1 Month Performance	N/A	0.56%	3.53%	1.47%
1 Year Performance	N/A	63.39%	34.04%	53.55%

Resverlogix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVX Resverlogix	N/A	C$0.10 -5.0%	N/A	+111.1%	C$30.11M	N/A	N/A	19	Gap Down
SCYB Scythian Biosciences	N/A	C$3.49 -5.9%	N/A	+0.0%	C$102.38M	N/A	N/A	N/A	High Trading Volume
COM 138267 (COM.TO)	N/A	N/A	N/A	N/A	C$102.19M	N/A	N/A	N/A
NVH Novoheart	N/A	C$0.53 +1.9%	N/A	+0.0%	C$99.98M	C$423.50K	N/A	N/A
IGX IntelGenx Technologies	N/A	C$0.58 +1.8%	N/A	+0.0%	C$87.32M	C$1.75M	N/A	2,050	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:RVX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Resverlogix (RVX) Competitors

RVX vs. SCYB, COM, NVH, IGX, and PDP

How does Resverlogix compare to Scythian Biosciences?

Summary

How does Resverlogix compare to 138267 (COM.TO)?

Summary

How does Resverlogix compare to Novoheart?

Summary

How does Resverlogix compare to IntelGenx Technologies?

Summary

How does Resverlogix compare to Pediapharm?

Summary

Media Sentiment Over Time

RVX vs. The Competition

Resverlogix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Resverlogix (RVX) Competitors

RVX vs. SCYB, COM, NVH, IGX, and PDP

How does Resverlogix compare to Scythian Biosciences?

Which has preferable valuation & earnings, SCYB or RVX?

Is SCYB or RVX more profitable?

Does the media prefer SCYB or RVX?

Do institutionals & insiders believe in SCYB or RVX?

Summary

How does Resverlogix compare to 138267 (COM.TO)?

Do insiders & institutionals hold more shares of COM or RVX?

Does the media refer more to COM or RVX?

Is COM or RVX more profitable?

Which has better earnings and valuation, COM or RVX?

Summary

How does Resverlogix compare to Novoheart?

Do institutionals and insiders hold more shares of RVX or NVH?

Is RVX or NVH more profitable?

Does the media prefer RVX or NVH?

Which has higher valuation and earnings, RVX or NVH?

Summary

How does Resverlogix compare to IntelGenx Technologies?

Is IGX or RVX more profitable?

Do institutionals and insiders hold more shares of IGX or RVX?

Which has stronger earnings & valuation, IGX or RVX?

Does the media favor IGX or RVX?

Summary

How does Resverlogix compare to Pediapharm?

Is PDP or RVX more profitable?

Which has higher valuation & earnings, PDP or RVX?

Does the media prefer PDP or RVX?

Do institutionals and insiders believe in PDP or RVX?

Summary

Media Sentiment Over Time

RVX vs. The Competition

Resverlogix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools